Oral small molecule GLP-1 receptor agonist
VCT220 80 mg tablet once daily
VCT220_PO_80MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.60 (0.43 to 94.41) | 0.19 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.85 (0.06 to 9.39) | 0.67 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.44 (2.33 to 14.48) | 0.31 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.58 (0.53 to 5.05) | 0.79 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.19 (0.76 to 6.59) | 0.44 |